Information de reference pour ce titreAccession Number: | 00007632-200611150-00002.
|
Author: | Korhonen, Timo MD *; Karppinen, Jaro MD, DMSc *+++; Paimela, Leena MD, DMSc ++; Malmivaara, Antti MD, DMSc ++; Lindgren, Karl-August MD, DMSc ++; Bowman, Chris DM-S [//]; Hammond, Anthony MD [P]; Kirkham, Bruce MD #; Jarvinen, Simo MD ++; Niinimaki, Jaakko MD **; Veeger, Nic MSc ++; Haapea, Marianne MSc **; Torkki, Markus MD, DMSc ++++; Tervonen, Osmo MD, DMSc **; Seitsalo, Seppo MD, DMSc ++; Hurri, Heikki MD, DMSc ++
|
Institution: | From the *Department of Physical Medicine and Rehabilitation, Oulu University Hospital, Oulu, Finland; +Department of Occupational Medicine, Finnish Institute of Occupational Health, Helsinki, Finland; ++ORTON Orthopaedic Hospital, Helsinki, Finland; [S]Finnish Office for Health Technology Assessment, Helsinki, Finland; [//]Tonbridge Clinic, Tonbridge, Kent, UK; [P]Maidstone Hospital, Kent, UK; #Rheumatology Department, Guy's & St. Thomas' NHS Foundation Trust, London, UK; **Department of Diagnostic Radiology, Oulu University Hospital, Oulu, Finland; ++Trial Coordination Center, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands; and ++++Dextra Medical Center, Helsinki, Finland.
|
Title: | |
Source: | Spine. 31(24):2759-2766, November 15, 2006.
|
Abstract: | Study Design. A randomized controlled trial.
Objectives. To evaluate the long-term efficacy of infliximab, a monoclonal antibody against tumor necrosis factor alpha (TNF-[alpha]), in patients with acute/subacute sciatica secondary to herniated disc.
Summary of Background Data. The results of experimental studies and our open-label trial support the use of infliximab in sciatica. Here we report the 1-year results of a randomized controlled trial (FIRST II, Finnish Infliximab Related STudy) evaluating the efficacy and safety of a single infusion of infliximab for sciatic pain.
Methods. Inclusion criteria were unilateral sciatic pain with a disc herniation concordant with the symptoms and signs of radicular pain. Patients had to be candidates for discectomy. Criteria for discectomy included (in addition to a symptomatic disc herniation on MRI) neural entrapment (straight leg raising [SLR] <=60[degrees]) with either a short-term (2-4 weeks) severe or long-term (4-12 weeks) moderate leg pain. Forty patients were allocated to a single intravenous infusion of either infliximab 5 mg/kg or placebo. Differences in the clinical examination parameters (straight leg raise [SLR], muscle strength, sensory defects, tendon reflexes), patient-reported symptoms (leg and back pain using a visual analog scale [VAS], Oswestry disability, quality-of-life [RAND-36]), sick leaves, number of discectomies, and adverse effects between the two treatment groups over the 1-year follow-up were compared using Mann-Whitney U test or Student's t test, repeated-measures analysis, or Cox proportional hazards model. Logistic regression was used to assess the predictors of good response.
Results. Sixty-seven percent of patients in the infliximab group reported no pain at 52 weeks compared with 63% in the control group (P = 0.72). Similar efficacy was observed between treatment groups for other outcomes. Eight patients in each group required surgery. Three nonserious adverse reactions were encountered in the infliximab group. The response (irrespective of the treatment) was significantly better with shorter symptom duration and less SLR restriction at baseline. Patients in the infliximab group appeared to especially benefit in cases of a L4-L5 (or L3-L4) herniation and if a Modic change was colocalized at the symptomatic level.
Conclusions. Although the long-term results of this randomized trial do not support the use of infliximab compared with placebo for lumbar radicular pain in patients with disc herniation-induced sciatica, further study in a subgroup of patients with L4-L5 or L3-L4 herniations, especially in the presence of Modic changes, appears to be warranted.
(C) 2006 Lippincott Williams & Wilkins, Inc.
|
Author Keywords: | sciatica; intervertebral disc herniation; TNF-[alpha]; conservative treatment; randomized controlled trial.
|
References: | 1. Igarashi T, Kikuchi S, Shubayev V, et al. Exogenous tumor necrosis factor-alpha mimics nucleus pulposus-induced neuropathology: molecular, histologic, and behavioral comparisons in rats. Spine 2000;25:2975-80.
2. Olmarker K, Rydevik B. Selective inhibition of tumor necrosis factor-alpha prevents nucleus pulposus-induced thrombus formation, intraneural edema, and reduction of nerve conduction velocity: possible implications for future pharmacologic treatment strategies of sciatica. Spine 2001;26:863-9.
3. Aoki Y, Rydevik B, Kikuchi S, et al. Local application of disc-related cytokines on spinal nerve roots. Spine 2002;27:1614-7.
4. Onda A, Yabuki S, Kikuchi S. Effects of neutralizing antibodies to tumor necrosis factor-alpha on nucleus pulposus-induced abnormal nociresponses in rat dorsal horn neurons. Spine 2003;28:967-72.
5. Karppinen J, Korhonen T, Malmivaara A, et al. Tumor necrosis factor-alpha monoclonal antibody, infliximab, used to manage severe sciatica. Spine 2003;28:750-3.
6. Genevay S, Stingelin S, Gabay C. Efficacy of etanercept in the treatment of acute and severe sciatica: a pilot study. Ann Rheum Dis 2004;63:1120-3.
7. Korhonen T, Karppinen J, Malmivaara A, et al. Efficacy of infliximab for disc herniation-induced sciatica: one-year follow-up. Spine 2004;29:2115-9.
8. Korhonen T, Karppinen J, Paimela L, et al. The treatment of disc herniation-induced sciatica with infliximab: results of a randomized, controlled, 3-month follow-up study. Spine 2005;30:2742-8.
9. Hays RD, Sherbourne CD, Mazel RM. The RAND 36-Item Health Survey 1.0. Health Econ 1993;2:217-27.
10. Hays RD, Morales LS. The RAND-36 measure of health-related quality of life. Ann Med 2001;33:350-7.
11. Aalto A-M, Aro AR, Teperi J. RAND-36 as a Measure of Health-Related Quality-of Life: The Reliability and Population Reference Values in Finland [in Finnish]. Helsinki: Stakes, 1999.
12. Allison PD. Survival Analysis Using the SAS System: A Practical Guide. Cary, NC: SAS Institute, 1995.
13. Boos N, Rieder R, Schade V, et al. 1995 Volvo Award in clinical sciences: the diagnostic accuracy of magnetic resonance imaging, work perception, and psychosocial factors in identifying symptomatic disc herniations. Spine 1995;20:2613-25.
14. Pfirrmann CW, Metzdorf A, Zanetti N, et al. Magnetic resonance classification of lumbar intervertebral disc degeneration. Spine 2001;26:1873-8.
15. Xie W, Strong JA, Meij JT, et al. Neuropathic pain: early spontaneous afferent activity is the trigger. Pain 2005;116:243-56.
16. Watkins LR, Maier SF. Beyond neurons: evidence that immune and glial cells contribute to pathological pain states. Physiol Rev 2002;82:981-1011.
17. Petrovic P, Kalso E, Petersson KM, et al. Placebo and opioid analgesia: imaging a shared neuronal network. Science 2002;295:1737-40.
18. Karppinen J, Ohinmaa A, Malmivaara A, et al. Cost effectiveness of periradicular infiltration for sciatica: subgroup analysis of a randomized controlled trial. Spine 2001;26:2587-95.
19. Osterman H, Seitsalo S, Karppinen J, et al. Effectiveness of microdiscectomy for lumbar disc herniation: a randomised controlled trial with two years of follow-up. Spine In Press.
|
Language: | English.
|
Document Type: | Randomized Trial.
|
Journal Subset: | Clinical Medicine.
|
ISSN: | 0362-2436
|
NLM Journal Code: | 7610646, uxk, 7610649
|
DOI Number: | https://dx.doi.org/10.1097/01.br...- ouverture dans une nouvelle fenêtre
|
Annotation(s) | |
|
|